

Retina Consultants
1220 New Scotland Rd
Slingerlands, NY 12159

Curriculum Vitae
Naomi Falk, M.D., O.D.

EDUCATION:

MEDICAL Albany Med, Albany NY, Retina Fellowship July 2002-2003
University of Texas, Houston TX, Retina Fellowship July 2001-2002.
Hahnemann University Hospital, Philadelphia PA, Ophthalmology, July 1998-2001 Lic. #MT-044124-T.
Winthrop University Hospital, Mineola NY, Internal Medicine, completed June 1998 Lic. #210696-1.
SUNY Health Science Center at Syracuse NY, M.D., June 1997.

OPTOMETRY SUNY College of Optometry, New York, NY, O.D., June 1989; Lic. # TOO4994.

COLLEGE Brandeis University, A.B., June 1985.

HONORS AND AWARDS:

MEDICAL Golden Apple Teaching Award 2003

OPTOMETRY Beta Sigma Kappa Honor Society
National Deans List

COLLEGE Cum Laude
Hebrew Language Award

PUBLICATIONS:

Simon J, Parikh H, Falk, N.
Excellent Visual Outcomes in Children with Myelinated Nerve Fibers and Without Myopia.
Submitted for Publication to Journal of AAPOS, 2016

Dedania V, Bhatnagar P, Falk N.
Ranibizumab 1.0 mg as rescue therapy for patients failing traditional therapy for Neovascular Age-Related Macular Degeneration
Accepted for Publication in Ophthalmic Surgery Laser and Imaging. 2015

Falk NS, Mali JO, Mali YP, Mencias L.
Endogenous Endophthalmitis With Iris Abscess After Routine Dental Cleaning.
JAMA Ophthalmology. 2/26/2015 (On line) jamaophthalmol.2015.12

Falk NS, Dedania VS, Hinkle DM, Au AK
Susac syndrome: recognizing the diagnosis
Submitted for Publication to Retinal Cases and Brief Reports

Hale BP, Au AK, Falk NS, Bhatnagar P, Beer PM.
Flat ERG and Acute Visual Loss Following Ocriplasmin Injection for Vitreomacular
Adhesion Complicating Macular Schisis
Submitted for Publication to OSLI Retina 2015

Holt H, Hinkle DM, Falk NS, Fraunfelder FT, Fraunfelder FW.
Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety 2014; 9: 65-68.

Wladis EJ, Falk NS, Iglesias BV, Beer PM, Gosselin EJ.
Analysis of the Molecular Biologic Milieu of the Vitreous in Proliferative
Vitreoretinopathy.
Retina. 2013 Apr;33(4):807-11

Au AK, Hinkle DM, Falk NS
The Role of Vitrectomy in the Management of Posterior Uveitis.
Retinal Physician January 2013

Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus Dryja, Andrew M. Wright, Irina
Koroleva, Gerard Bruin, Christian Antoni, Zoe Draelos, Michael H. Gold, the Psoriasis
Study Group, Patrick Durez, Paul P. Tak, Juan J. Gomez-Reino, the Rheumatoid Arthritis
Study Group, C. Stephen Foster, Rosa Y. Kim, C. Michael Samson, Naomi S. Falk,
David S. Chu, David Callanan, Quan Dong Nguyen, the Uveitis Study Group, Kristine
Rose, Asifa Haider, and Franco Di Padova
Effects of AIN457, a Fully Human Antibody to Interleukin-17a, on Psoriasis,
Rheumatoid Arthritis, and Uveitis.
Sci Transl Med 6 Oct 2010 Vol. 2 Issue 52, p. 52ra72

Beer PM, Wong SJ, Schartman JP, Kulas KE, Hartman CL, Giganti M, Falk NS.
Infliximab Stability after Reconstitution, Dilution, and Storage under Refrigeration..
Retina 2010 Jan; 30(1):81-84.

S Itty¹, S J Bakri², J S Pulido², D C Herman², L J Faia², G T Tufty³, S R Bennett⁴ and
N S Falk
Initial results of QuantiFERON-TB Gold testing in patients with uveitis. Eye (2009) 23,
904-909

Naomi S. Falk, Paul M. Beer, Kim Stepien, Pamela Kaw, George B. Peters III
Increased Choroidal Nonperfusion after Combination Therapy with Verteporfin and
Intravitreal Triamcinolone Acetonide for Subfoveal Choroidal Neovascularization in Age
Related Macular Degeneration
Submitted to Retina for publication

Naomi S. Falk, Paul M. Beer, George B. Peters III. Role of Intravitreal Triamcinolone
Acetonide for the Treatment of Postoperative Endophthalmitis
Retina. 26(5):545-548, May/June 2006

Costello P, Bakri SJ, **Beer PM**, Singh R, Falk N, Peters G, Melendez JA: Vitreous

Penetration of Topical Moxifloxacin and Gatifloxacin in Humans. *Retina* February 2006. 26(2):191-5.

Naomi S. Falk, Sophie J. Bakri, Paul M. Beer, George B. Peters III. Intravitreal Preservative-Free Triamcinolone Acetonide for the treatment of Macular Edema. **Eye**. 2005 June; 19(6):686-8.

Paul M. Beer, Sophie J. Bakri, Naomi S. Falk, George B. Peters III. Verteporfin Photodynamic Therapy for Macular Edema Due to Radiation Retinopathy. To be submitted for publication *Ophthalmology*

Jonathan A. Nickel, Sophie J. Bakri, Paul M. Beer, Naomi S. Falk, George B. Peters III. Verteporfin Photodynamic Therapy for Neovascular Age Related Macular Degeneration Associated with Subretinal Hemorrhage. To be submitted for publication *Ophthalmology*

“The Primary Care Optometric Evaluation of the Traumatic Brain Injury Patient.” Falk NS, Aksionoff EB. *J Am Optom Assoc*. 1992; 63:547-53.

“Differential Diagnosis of Perceptual Deficits in Brain Injury Patients.” Aksionoff EB, Falk NS. *J Am Optom Assoc*. 1992; 63:554-8.

“Optometric Therapy for Left Brain Injured Patient.” Aksionoff EB, Falk NS. *J Am Optom Assoc*. 1992; 63:564-8.

“Drug Induced Effects on Secretion of the Rat Lacrimal Gland.” Poster Session, American Academy of Optometry; Toronto. Canada; December 1986.

EXPERIENCE:

CLINICAL:

Clinical Professor, Albany Medical Center with surgical privileges at Albany Medical Center, Childs Hospital and Albany Memorial Hospital
July 2003- present.

Practicing in full scope retina and uveitis including management of medical and surgical disease, iodine plaque therapy for choroidal melanoma, Immune modulatory therapy for uveitis plus participation in multi-center clinical trials for macular degeneration, diabetes, venous occlusions, macular edema and uveitis July 2003-present.

Vitreoretinal Fellow, Albany Medical Center July 2002-June 2003.

Vitreoretinal Fellow, University of Texas, July 2001-June 2002.

Chief Resident, Hahnemann University Hospital, July 2000 – June 2001.

Ophthalmology Resident, Hahnemann University Hospital, July 1998 –June 2001.

Medical Intern, Winthrop University Hospital, July 1997 – June 1998.

Assistant Clinical Professor, SUNY College of Optometry, July 1990 – June 1993.

Staff Optometrist and Clinical Instructor, Veterans Hospital, Northport, NY, June 1990 - June 1993.

Optometric Resident, Veterans Hospital, Northport, NY. Full scope clinical program includes Primary care, Pathology, Low Vision, Contact lenses, Vision Therapy and Head Trauma rehabilitation, July 1989 – June 1990.

RESEARCH/MULTI-CENTER STUDIES:

AVENUE (Roche BP29647) 2016-Present
A Multiple-Center, Multi-Dose and regimen, randomized, active comparator controlled, double masked, parallel group, 36 week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of R06867461 administered intravitreally in patients with choroidal neovascularization secondary to Age-Related Macular Degeneration.
Principal Investigator

Hawk (Alcon RTH258) 2016-Present
A two-year, randomized, double masked, multi-center, three-arm study comparing the efficacy and safety of RTH258 versus Afibercept in subjects with Neovascular Age-Related Macular Degeneration.
Principal Investigator

Clearside PEACHTREE (Chiltern) 2016-Present
A Phase 3, RandomizEd, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects with Macular Edema associated with Non-Infectious Uveitis.
Principal Investigator

Sanofi 2013-Present
A randomized, double-masked and placebo-controlled study to evaluate the efficacy and safety of sarilumab administered subcutaneously every 2 weeks in patients with Non-infectious, Intermediate, Posterior or Pan-Uveitis (NIU)
Principal Investigator

pSivida 2013-Present
Flucinolone Acetonide Intravitreal Insert Protocol PSV-FAI-001
Phase III, Multi-National, Multi-center, Randomized, masked, controlled, safety and efficacy study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
Principal Investigator

Sakura 32-007 (Santen) 2011-- 2012
Dose escalation using intravitreal Sirolimus for noninfectious posterior uveitis (Phase III)
Principal Investigator

Novartis AIN457 Cohort 6 2011

Intravenous vs Subcutaneous administration of AIN457 for noninfectious posterior or panuveitis (Double Blinded)
Principal Investigator

Novartis AIN457 Cohort 5 2011-2013
Open Label High dose Intravenous AIN457 (30mg/kg) for noninfectious posterior or Panuveitis
Principal Investigator

INSURE Study 2010
Novartis AIN457 versus placebo for noninfectious intermediate, posterior or panuveitis (Phase III)
Principal Investigator

Novartis CAIN457A2208 (ENDURE) 2008-present
Assess effects with 2 different doses AIN457 for noninfectious uveitis (Phase II)
Principal Investigator
Cytokine Concentrations in Primary Retinal Detachment and Proliferative Vitreoretinopathy 2010-1011
Principal Investigator

Ophthotec OPH 1001 2008-2011
Sub-Investigator

Ophthotec OPH 3000 2008-2010
Sub- Investigator

Ophthotec OPH 1000 2008-2009
Sub- Investigator

Regeneron [VGFT-06-05] 2007-2010
VEGF trap for Neovascular AMD
Sub-Investigator

RIDE [FVF4168g] 2007-present
Genentech: Lucentis for Diabetic Macular edema
Sub-Investigator

SALVAGE FVF3933 2007-2009
Phase I/II study to evaluate Scotoma Reduction and Limited Visual Acuity in Age Related Macular Degeneration. Patients Treated with Intravitreal Ranibizumab.
Sub-Investigator

AREDS II 2006-present
AREDS 2 The Age- Related Eye Disease Study 2.
Sponsored by the National Eye Institute of Health

Foresee home (Addendum to AREDS II) 2010
Sponsored by National Eye Institute of Health

Arrxant [B7A-MC-MBCU] 2006-2008
Roboxistaurin for diabetic macular edema
Principal Investigator

Sailor I and Sailor II [FVF3689g] 2005-2007
Phase II, Multi-Center Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization Secondary to Macular Degeneration

Horizon FVF3426g. An Open-Label, Multi-Center 2005-2008
Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) Who have Completed the Treatment Phase of a Genetech-Sponsored Ranibizumab Study.

Pegaptanib Sodium [Macugen]; EOP1010 2005
Compassionate trial

Intravitreal Triamcinolone for Diabetic 2004-2007
Macular Edema Study. Diabetic Retinopathy
Clinical Research Study 1-B, National Eye Institute
Study Protocol Planning Committee

Dexamethasone Posterior Segment Drug Delivery 2004-2006
System (Posurdex) in Treatment of Patients with
Macular Edema secondary to Retinal Vein Occlusion.

Pegaptanib Sodium [EYE001; Macugen] 2003-2005
versus PDT with Visudyne; EOP 1008
Sub-Investigator

Pilot Laser Photocoagulation for Diabetic 2003-2005
Macular Edema Study. Diabetic Retinopathy
Clinical Research Study 1-A, National Eye Institute
Sub-Investigator.

Efficacy and Safety of rhuFab V2 Compared to 2003-2005
Verteporfin photodynamic Therapy in Subjects with
Predominantly Classic Subfoveal Neovascular Age-Related
Macular Degeneration
ANCHOR Sub-Investigator

Minimally classic/occult trial of the Antivegf 2003-2005
Antibody Rhufab in the treatment of
Neovascular Age related Macular Degeneration
MARINA Sub-Investigator

Prospective and Retrospective Demographic Study of Treatment Regimens for Ocular
Trauma, June 1993 – August 1993.

Laboratory Evaluation of Peroxidase Secretion, Stimulation of Potassium and Phosphate Production in the Rat Lacrimal Gland (Advisor: John Picarelli, PhD.), 1986 – 1988.

Experiments evaluating deposits occurring on soft contact lenses (Advisor: Jerold Rapp, PhD.), 1985 – 1986.

PRESENTATIONS:

Cytokine Concentrations in Primary Retinal Detachment and Proliferative Vitreoretinopathy EJ Wladis MD FACS, NS Falk MD, BV Iglesias BAPM Beer MD, EJ Gosselin PhD Submitted to Academy presentation. 2013

Naomi Falk

Vascular disease

AOU Conference 2010 (Albany Ophthalmology Update)

Naomi S. Falk MD

Retisert Implant for Birdshot Chorioretinopathy.

Poster session ASRS 2008

Naomi Falk

Central Retinal Artery Occlusion Treatment and Management.

Ocular Immunology and Uveitis Foundation Physician Education Conference

Boston October 2007

Naomi Falk. Standard of Care Monitoring Macular Degeneration.

Ocular Immunology and Uveitis Foundation Physician Education Conference

Boston October 2007

Naomi Falk, Paul Beer, George Peters III. Role of Intravitreal triamcinolone Acetonide for the treatment of postoperative endophthalmitis.

Annual meeting of the American Society of Retina Specialists, Montreal, Canada July 2005

Naomi S. Falk, Paul M. Beer, Kim Stepien, Pamela Kaw, George B. Peters III

Increased Choroidal Nonperfusion after Combination Therapy with Verteporfin and Intravitreal Triamcinalone Acetonide for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration

Poster session at annual meeting of the American Society of Retina Specialists, Montreal, Canada July 2005

Kimberly E Stepien, Paul M Beer, George Peters III, Naomi Falk. Optical coherence tomography findings in the macula of patients undergoing pneumatic retinopexy for rhegmatogenous retina detachment.

Poster session at annual meeting of the American Society of Retina Specialists, Montreal, Canada July 2005

Paul M. Beer, Sophie J. Bakri, Naomi S. Falk, George B. Peters III. Verteporfin Photodynamic Therapy for Macular Edema Due to Radiation Retinopathy. 21st Annual Meeting of the American Society of Retina Specialists, N.Y.C. NY August 20, 2003

Naomi S. Falk, Sophie J. Bakri, Paul M. Beer, George B. Peters III. Intravitreal Preservative-Free Triamcinolone Acetonide for the treatment of Macular Edema. 21st Annual Meeting of the American Society of Retina Specialists, N.Y.C. NY August 20, 2003

Jonathan A. Nickel, Sophie J. Bakri, Paul M. Beer, Naomi S. Falk, George B. Peters III. Verteporphin Photodynamic Therapy for Neovascular Age Related Macular Degeneration Associated with Subretinal Hemorrhage. 21st Annual Meeting of the American Society of Retina Specialists, N.Y.C. NY August 18, 2003

Falk, N. Anti-VEGF compounds for the Treatment of Macular Degeneration An Update for Eye Care Providers. Guest Lecturer: The Johns Hopkins University: Albany Institute of Art. Albany, N.Y., June 18, 2003

Falk, N Developments in Macular Degeneration
Glens Falls Primary Eye Care Conference
Glens Falls, N.Y., May 5, 2003